Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, exerts its biological effects by binding to the repulsive guidance molecule A (RGMa), which in turn enhances locomotor function and promotes neuroregeneration. Unasnemab (MT-3921) demonstrates potential utility in the field of spinal cord injury research, where it provides an experimental approach to explore regenerative therapies targeting inhibitory guidance molecules.
Reinheit:
98.30%
CAS Nummer:
[2379805-59-9]
Target-Kategorie:
RGM
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten